Four-year data show preservation of cardiac function, including LVEF Skeletal muscle disease progression continues to slow with extended treatment (PUL v2.0) Deramiocel’s long-term safety profile ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results